Sponsor or institution

Clinical trials and research at Merck Sharp & Dohme LLC

• 115Clinical trials
• 1New in 30 days
• 69Countries

Newest trials

All recruiting trials (115)

• Ensa?fentrine to help prevent COPD flare-ups in adults on standard care

  This study tests whether ensifentrine (MK-5884) can help prevent moderate or severe COPD exacerbations compared with placebo in adults already receiving standard COPD treatment.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Hialeah Gardens, Florida and 6 other locations · NCT07874815

• Tulisokibart for active pulmonary sarcoidosis: a phase 2 trial

  This phase 2 trial tests tulisokibart versus placebo to see if it can slow the worsening of active pulmonary sarcoidosis in adults.

  Recruiting Phase 2 Merck Sharp & Dohme LLC · Shreveport, Louisiana · NCT07867938

• Tulisokibart for non-infectious uveitis in adults

  This trial tests tulisokibart vs placebo to see if it can extend the time before NIIPPU worsens in people with noninfectious intermediate, posterior, or panuveitis.

  Recruiting Phase 2 Merck Sharp & Dohme LLC · Plano, Texas · NCT07861074

• V175 and V175A vaccines in healthy adults

  This study tests two RSV vaccines (V175 and V175A) in healthy adults to see if they are safe and well tolerated.

  Recruiting at 2 sites Phase 1 Merck Sharp & Dohme LLC · Brisbane, Queensland and 1 other locations · NCT07855510

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Enlicitide (MK-0616) for adults with high cholesterol in India

  This study tests whether enlicitide helps lower bad cholesterol (LDL-C) compared with placebo in adults with hyperlipidemia/hypercholesterolemia.

  Recruiting at 2 sites Phase 3 Merck Sharp & Dohme LLC · Belagavi, Karnataka and 1 other locations · NCT07821944

• MK-2010 alone or with other treatments for advanced solid tumors

  This trial tests MK-2010, by itself or with other cancer medicines, to see if it helps people with advanced solid tumors.

  Recruiting at 7 sites Phase 2 Merck Sharp & Dohme LLC · Belleville, New Jersey and 6 other locations · NCT07793942

• V503-108: See if the 9-valent HPV vaccine boosts protection in Chinese women who already got the bivalent HPV vaccine

  In Chinese women who previously received the bivalent HPV vaccine, this study tests whether the 9-valent HPV vaccine (V503) can trigger an immune response to additional HPV types.

  Recruiting Phase 3 Merck Sharp & Dohme LLC · Taizhou, Zhejiang · NCT07785843

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Raludotatug Deruxtecan with or without Bevacizumab for advanced ovarian, peritoneal, or fallopian tube cancer

  This trial tests whether adding raludotatug deruxtecan (R-DXd) to or without bevacizumab helps people with advanced ovarian cancer that progressed after PARP-inhibitor maintenance.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Fountain Valley, California and 6 other locations · NCT07743164

• MK-1406: testing how the body handles two vs. three injections in healthy adults

  This early-phase study tests how MK-1406 behaves in healthy people when given as two injections versus three injections to see if it is safe and tolerable.

  Recruiting at 7 sites Phase 1 Merck Sharp & Dohme LLC · Hollywood, Florida and 6 other locations · NCT07743151

• Nemtabrutinib in people with severe kidney disease and healthy volunteers

  This study tests how nemtabrutinib behaves in the bodies of people with severe kidney impairment and in healthy volunteers.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Miami Lakes, Florida · NCT07734610

• Test of bomedemstat for polycythemia vera in adults

  This study tests bomedemstat (MK-3543) to see if it helps people with polycythemia vera reach healthier blood counts compared with standard treatments.

  Recruiting at 5 sites Phase 2/3 Merck Sharp & Dohme LLC · Newark, Delaware and 4 other locations · NCT07722611

• V132 vaccine safety in healthy older adults

  This study tests the safety and immune response of V132 formulations in healthy older adults to see if the vaccine is safe and prompts an immune reaction.

  Recruiting at 10 sites Phase 1 Merck Sharp & Dohme LLC · Anaheim, California and 9 other locations · NCT07712575

• MK-1045-006: testing a new treatment for B-cell cancers like CLL and SLL

  This trial will test MK-1045 in people with relapsed or treatment‑refractory CLL/SLL to see if it’s safe and how well it works.

  Recruiting at 8 sites Phase 2 Merck Sharp & Dohme LLC · Medellín, Antioquia and 7 other locations · NCT07709000

• MK-8748 vs. aflibercept for diabetic macular edema

  This trial tests whether the investigational medicine MK-8748 can treat diabetic macular edema as well as the standard treatment aflibercept in adults with diabetes.

  Recruiting at 20 sites Phase 3 Merck Sharp & Dohme LLC · Long Beach, California and 19 other locations · NCT07705607

• MK-8748 vs aflibercept for diabetic macular edema

  This trial tests whether MK-8748 can treat diabetic macular edema as well as the standard treatment aflibercept in people with diabetes.

  Recruiting at 35 sites Phase 3 Merck Sharp & Dohme LLC · Gilbert, Arizona and 34 other locations · NCT07705555

• Belzutifan in adolescents with solid tumors

  This study tests belzutifan in teenagers whose solid tumors can't be removed by surgery or have spread.

  Recruiting at 10 sites Phase 2 Merck Sharp & Dohme LLC · Iowa City, Iowa and 9 other locations · NCT07700758

• Sotatercept in Japanese children with pulmonary arterial hypertension

  This study tests whether sotatercept is safe and well tolerated in Japanese children with PAH when added to standard PAH treatment.

  Recruiting at 3 sites Phase 2 Merck Sharp & Dohme LLC · Izumi, Osaka and 2 other locations · NCT07646860

• MK-1045 and Rituximab in Follicular Lymphoma

  This study tests whether adding MK-1045 to rituximab can help people with follicular lymphoma after standard therapy.

  Recruiting at 38 sites Phase 2/3 Merck Sharp & Dohme LLC · Duarte, California and 37 other locations · NCT07634471

• Ifinatamab Deruxtecan in kids with relapsed or refractory solid cancers

  This study tests whether I-DXd can help children whose solid tumors have come back or not responded to previous treatments.

  Recruiting at 35 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 34 other locations · NCT07630974

• MK-7262 and Enlicitide in people with high lipoprotein(a)

  This trial tests whether MK-7262, alone or with enlicitide, lowers Lp(a) and LDL-C in people on stable statin therapy.

  Recruiting at 76 sites Phase 2 Merck Sharp & Dohme LLC · Alexander City, Alabama and 75 other locations · NCT07614984

• MK-4884 safety in advanced solid tumors

  This early-phase study tests different doses of MK-4884 to see if it is safe and tolerable for adults with certain advanced solid cancers.

  Recruiting at 10 sites Phase 1 Merck Sharp & Dohme LLC · St Louis, Missouri and 9 other locations · NCT07600749

• Sotatercept in Indian adults with pulmonary arterial hypertension on standard therapy

  This study tests whether adding sotatercept to current PAH medicines is safe and tolerable for adults with PAH in India.

  Recruiting at 3 sites Phase 4 Merck Sharp & Dohme LLC · Hyderabad, Andhra Pradesh and 2 other locations · NCT07600723

• MK-1045 versus blinatumomab for relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia

  This trial will test whether MK-1045 helps people with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia more than the standard immunotherapy blinatumomab.

  Recruiting at 30 sites Phase 2/3 Merck Sharp & Dohme LLC · Toronto, Ontario and 29 other locations · NCT07570173

• Calderasib plus durvalumab in KRAS G12C NSCLC after chemo-radiation

  This trial tests whether calderasib plus durvalumab can help people with locally advanced KRAS G12C NSCLC who have completed chemotherapy and radiation, compared with placebo plus durvalumab.

  Recruiting at 115 sites Phase 3 Merck Sharp & Dohme LLC · Savannah, Georgia and 114 other locations · NCT07554339

• MK-1045 for follicular lymphoma and diffuse large B-cell lymphoma

  This trial tests MK-1045 in people with follicular lymphoma or diffuse large B-cell lymphoma to see if the treatment is safe and tolerable and whether the cancer shrinks or disappears.

  Recruiting at 54 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 53 other locations · NCT07519772

• Adjuvant intismeran (V940) with or without pembrolizumab plus berahyaluronidase alfa for high‑risk Stage I non‑small cell lung cancer after surgery

  This trial will try intismeran (V940) alone or together with subcutaneous pembrolizumab plus berahyaluronidase alfa to help prevent recurrence in people with completely removed high‑risk Stage I non‑small cell lung cancer.

  Recruiting at 126 sites Phase 3 Merck Sharp & Dohme LLC · Sacramento, California and 125 other locations · NCT07513376

• Belzutifan plus zanzalintinib versus belzutifan alone for advanced renal cell carcinoma

  This trial tests whether adding the targeted drug zanzalintinib to belzutifan helps people with advanced renal cell carcinoma live longer and delay tumor growth compared with belzutifan plus placebo.

  Recruiting at 107 sites Phase 3 Merck Sharp & Dohme LLC · Duarte, California and 110 other locations · NCT07489495

• MK-8690 for moderately to severely active ulcerative colitis

  This trial will test whether the investigational drug MK-8690 can help adults with moderate to severe ulcerative colitis reach clinical remission by week 12.

  Recruiting at 39 sites Phase 2 Merck Sharp & Dohme LLC · Anaheim, California and 38 other locations · NCT07463183

• Adjuvant calderasib with subcutaneous pembrolizumab plus berahyaluronidase alfa for completely resected KRAS G12C stage IIA–IIIB (N2) NSCLC

  This trial tests whether adding the oral KRAS G12C inhibitor calderasib to subcutaneous pembrolizumab plus berahyaluronidase alfa helps prevent recurrence in people with completely resected stage IIA–IIIB (N2) KRAS G12C non‑small cell lung cancer.

  Recruiting at 122 sites Phase 3 Merck Sharp & Dohme LLC · Ciudad Autónoma de Buenos Aires, Buenos Aires and 121 other locations · NCT07431827

• Sacituzumab tirumotecan versus non‑platinum chemotherapy for advanced bladder cancer

  This trial will test whether sacituzumab tirumotecan can help people with advanced urothelial (bladder) cancer live longer than certain non‑platinum chemotherapies after their disease worsens following prior treatments.

  Recruiting at 113 sites Phase 3 Merck Sharp & Dohme LLC · Newport Beach, California and 112 other locations · NCT07419295

• Extension program for people previously treated with belzutifan (MK-6482)

  This extension lets people with advanced solid tumors or VHL-related tumors who were already taking belzutifan in another study continue the drug so researchers can see how long they live and watch for long-term effects.

  Recruiting at 50 sites Phase 3 Merck Sharp & Dohme LLC · Boston, Massachusetts and 56 other locations · NCT07405164

• Ifinatamab deruxtecan for advanced esophageal squamous cell carcinoma

  This trial will test whether ifinatamab deruxtecan can shrink or eliminate advanced esophageal squamous cell carcinoma in people whose cancer progressed after one or two prior systemic treatments.

  Recruiting at 34 sites Phase 1/2 Merck Sharp & Dohme LLC · Pittsburgh, Pennsylvania and 33 other locations · NCT07405151

• MK-1045 for people with lupus or rheumatoid arthritis

  This research tests the experimental medicine MK-1045 to see if it is safe and tolerable in adults with lupus or rheumatoid arthritis.

  Recruiting at 20 sites Phase 1 Merck Sharp & Dohme LLC · Southport, Queensland and 20 other locations · NCT07363590

• Sac-TMT maintenance for people with non-HRD advanced ovarian cancer

  This trial sees if sacituzumab tirumotecan (sac‑TMT), given with or without bevacizumab, can keep cancer from getting worse after surgery and first‑line platinum chemotherapy in people with non‑HRD advanced ovarian cancer.

  Recruiting at 177 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 176 other locations · NCT07318558

• Pembrolizumab treatment for Japanese children with solid tumors or lymphomas and Japanese adults with Merkel cell carcinoma

  This study will try pembrolizumab in Japanese children with solid tumors or lymphomas and in Japanese adults with Merkel cell carcinoma to learn about safety, how the drug moves through the body, and whether tumors shrink.

  Recruiting at 7 sites Phase 1/2 Merck Sharp & Dohme LLC · Nagoya, Aichi-ken and 6 other locations · NCT07302347

• V118C pneumococcal vaccine in infants and toddlers

  This will try a new pneumococcal vaccine called V118C in infants and toddlers to check safety and how well they tolerate it.

  Recruiting at 15 sites Phase 1 Merck Sharp & Dohme LLC · Madera, California and 14 other locations · NCT07300267

• MK-1084 combined with other therapies for advanced non-squamous non-small cell lung cancer

  This trial tests whether MK-1084 given with other anti-cancer drugs can shrink tumors in people with advanced or metastatic non-squamous NSCLC who have a KRAS G12C mutation and have progressed after prior platinum chemotherapy and PD-(L)1 therapy.

  Recruiting at 29 sites Phase 1/2 Merck Sharp & Dohme LLC · Clermont, Florida and 28 other locations · NCT07286149

• Once-weekly islatravir plus ulonivirine for people with untreated HIV-1

  This trial tests whether a once-weekly oral combination of islatravir and ulonivirine can control HIV-1 in people who have never taken antiretroviral therapy.

  Recruiting at 53 sites Phase 2/3 Merck Sharp & Dohme LLC · Los Angeles, California and 55 other locations · NCT07266831

• Pembrolizumab plus MK-1084 for NSCLC with KRAS G12C mutation

  This trial tests whether adding the targeted drug MK-1084 to pembrolizumab helps people with advanced non‑small cell lung cancer that has a KRAS G12C mutation.

  Recruiting at 39 sites Phase 2 Merck Sharp & Dohme LLC · Clermont, Florida and 39 other locations · NCT07252739

• MK-4716 for certain advanced solid tumors

  This trial will test whether the oral drug MK-4716, given alone or with pembrolizumab or cetuximab, is safe and tolerable for people with advanced or metastatic solid tumors that have KRAS gene changes.

  Recruiting at 21 sites Phase 1 Merck Sharp & Dohme LLC · New Brunswick, New Jersey and 20 other locations · NCT07247110

• Adding MK-3120 to enfortumab vedotin and pembrolizumab for advanced urothelial (bladder) cancer

  This study tests whether adding the investigational drug MK-3120 to standard enfortumab vedotin plus pembrolizumab helps people with locally advanced or metastatic urothelial (bladder) cancer.

  Recruiting at 17 sites Phase 1/2 Merck Sharp & Dohme LLC · San Francisco, California and 16 other locations · NCT07232602

• Gocatamig and ifinatamab deruxtecan combined with standard therapy for extensive-stage small cell lung cancer

  This trial tests whether giving gocatamig and ifinatamab deruxtecan, alone or with standard chemotherapy plus immunotherapy, helps people with extensive-stage small cell lung cancer.

  Recruiting at 58 sites Phase 1/2 Merck Sharp & Dohme LLC · Santa Rosa, California and 57 other locations · NCT07227597

• Belzutifan plus zanzalintinib versus cabozantinib for recurrent advanced kidney cancer after adjuvant PD-1/L1 therapy

  This study will test whether taking belzutifan together with zanzalintinib helps people with recurrent advanced kidney cancer live longer and keep the cancer from getting worse compared with cabozantinib after prior adjuvant PD-1/L1 therapy.

  Recruiting at 127 sites Phase 3 Merck Sharp & Dohme LLC · Anchorage, Alaska and 126 other locations · NCT07227402

• MK-3120 treatment for high-risk non‑muscle invasive bladder cancer (CIS ± papillary)

  We will test whether MK-3120 can be given safely and is tolerated by people with high‑risk non‑muscle invasive bladder cancer after tumor removal (TURBT).

  Recruiting at 12 sites Phase 1/2 Merck Sharp & Dohme LLC · Bakersfield, California and 16 other locations · NCT07222488

• Intismeran autogene plus pembrolizumab and chemotherapy for metastatic squamous non-small cell lung cancer

  This trial will test whether adding intismeran autogene to pembrolizumab and chemotherapy helps people with treatment‑naive metastatic squamous non‑small cell lung cancer live longer and keep their cancer from growing.

  Recruiting at 55 sites Phase 2 Merck Sharp & Dohme LLC · Tampa, Florida and 54 other locations · NCT07221474

• Sacituzumab tirumotecan plus pembrolizumab as first-line maintenance for metastatic cervical cancer

  This trial tests whether adding the antibody-drug conjugate sacituzumab tirumotecan to pembrolizumab (with or without bevacizumab) as maintenance treatment can help people with metastatic cervical cancer live longer or keep the cancer from growing.

  Recruiting at 191 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 190 other locations · NCT07216703

• Calderasib (MK-1084) with or without cetuximab for advanced KRAS G12C solid tumors

  This study will test whether calderasib (MK-1084), alone or combined with cetuximab, can shrink advanced solid tumors in people whose cancers have the KRAS G12C mutation.

  Recruiting at 71 sites Phase 2 Merck Sharp & Dohme LLC · Baltimore, Maryland and 71 other locations · NCT07209111

• Letermovir to prevent CMV in children and adolescents after kidney transplant

  This study will test whether the antiviral letermovir can safely prevent cytomegalovirus (CMV) in children and adolescents under 40 kg who recently received a kidney transplant.

  Recruiting at 22 sites Phase 1 Merck Sharp & Dohme LLC · Birmingham, Alabama and 21 other locations · NCT07199465

• Calderasib plus subcutaneous pembrolizumab for KRAS G12C non-small cell lung cancer

  This trial will test whether adding the KRAS G12C drug calderasib to subcutaneous pembrolizumab helps people with advanced nonsquamous non‑small cell lung cancer live longer without the cancer growing compared with pembrolizumab plus chemotherapy.

  Recruiting at 221 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 224 other locations · NCT07190248

• Tulisokibart (MK-7240) for radiographic axial spondyloarthritis

  This trial will test tulisokibart (MK‑7240) in adults with radiographic axial spondyloarthritis to see if it reduces spine and pelvic joint pain and stiffness compared with placebo.

  Recruiting at 93 sites Phase 2 Merck Sharp & Dohme LLC · Chandler, Arizona and 106 other locations · NCT07133633

• Monthly MK-8527 to prevent HIV-1 infection

  This study will test whether taking MK-8527 once a month prevents HIV-1 better than daily oral PrEP in HIV-negative, sexually active cisgender women.

  Recruiting at 21 sites Phase 3 Merck Sharp & Dohme LLC · Homabay County, Homa Bay County and 29 other locations · NCT07071623

• Patritumab deruxtecan for HR+/HER2- unresectable locally advanced or metastatic breast cancer

  This trial tests whether patritumab deruxtecan helps people with hormone receptor–positive, HER2‑negative advanced breast cancer who have progressed on CDK4/6 inhibitor plus endocrine therapy live longer or have slower cancer growth compared with standard chemotherapy.

  Recruiting at 203 sites Phase 3 Merck Sharp & Dohme LLC · Daphne, Alabama and 205 other locations · NCT07060807

• Enlicitide decanoate (MK-0616), an oral PCSK9 inhibitor, for children and adolescents with heterozygous familial hypercholesterolemia

  This trial tests whether a daily oral medicine called enlicitide decanoate can safely lower LDL cholesterol in children and teens with heterozygous familial hypercholesterolemia.

  Recruiting at 48 sites Phase 2/3 Merck Sharp & Dohme LLC · Wilmington, Delaware and 47 other locations · NCT07058077

• Combination belzutifan plus zanzalintinib for recurrent clear cell renal cell carcinoma after anti‑PD‑(L)1 adjuvant therapy

  This study tests whether combining belzutifan and zanzalintinib is safe and active for people whose clear cell renal cell carcinoma came back during or within 24 months after anti‑PD‑(L)1 adjuvant therapy.

  Recruiting at 33 sites Phase 1/2 Merck Sharp & Dohme LLC · San Francisco, California and 32 other locations · NCT07049926

• MK-2214 for people with early Alzheimer's disease

  This trial will test whether the drug MK-2214 can slow the spread of tau protein in the brains of people with mild cognitive impairment or mild dementia from Alzheimer's disease.

  Recruiting at 79 sites Phase 2 Merck Sharp & Dohme LLC · Irvine, California and 79 other locations · NCT07033494

• MK-8294 for people with advanced metastatic solid tumors

  This will try MK-8294, a targeted cancer drug, in people with advanced or metastatic solid tumors to find the highest dose that is safe and tolerable.

  Recruiting at 8 sites Phase 1 Merck Sharp & Dohme LLC · Chicago, Illinois and 7 other locations · NCT07030712

• Calderasib plus cetuximab and chemotherapy for KRAS G12C colorectal cancer

  This trial will test whether adding calderasib and cetuximab to mFOLFOX6 helps people with unresectable locally advanced or metastatic colorectal cancer that has a KRAS G12C mutation live longer without their cancer growing.

  Recruiting at 244 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 244 other locations · NCT06997497

• MK-5684 for breast, ovarian, and endometrial cancer

  This trial will test whether MK-5684 helps people with certain breast, ovarian, or endometrial cancers live longer without the disease growing or spreading.

  Recruiting at 60 sites Phase 2 Merck Sharp & Dohme LLC · Anchorage, Alaska and 59 other locations · NCT06979596

• Sacituzumab tirumotecan plus pembrolizumab and chemotherapy for high-risk early triple-negative and HR-low/HER2-negative breast cancer

  This trial will test whether adding sacituzumab tirumotecan and pembrolizumab to chemotherapy helps people with high‑risk early-stage triple‑negative or HR‑low/HER2‑negative breast cancer have fewer cancer cells in their tumors and lymph nodes before surgery.

  Recruiting at 331 sites Phase 3 Merck Sharp & Dohme LLC · Gilbert, Arizona and 334 other locations · NCT06966700

• Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab alone for pMMR endometrial cancer

  This trial tests whether adding sacituzumab tirumotecan to pembrolizumab helps people with advanced or recurrent mismatch repair–proficient endometrial cancer live longer without their cancer getting worse compared to pembrolizumab alone.

  Recruiting at 266 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 270 other locations · NCT06952504

• Patritumab deruxtecan for children with relapsed or refractory hepatoblastoma or rhabdomyosarcoma

  This trial tests an antibody-drug conjugate called HER3-DXd (patritumab deruxtecan) to see if it is safe and can shrink relapsed or treatment-resistant hepatoblastoma or rhabdomyosarcoma in children.

  Recruiting at 64 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 63 other locations · NCT06941272

• New treatment for metastatic prostate cancer using ifinatamab deruxtecan

  This study is testing a new treatment called ifinatamab deruxtecan to see if it helps men with advanced prostate cancer live longer and feel better compared to standard chemotherapy.

  Recruiting at 290 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 302 other locations · NCT06925737

• Comparing two treatments for a type of blood cancer called DLBCL

  This study is testing whether a new combination of treatments can help people with a specific type of blood cancer feel better compared to the standard treatment.

  Recruiting at 146 sites Phase 2 Merck Sharp & Dohme LLC · Mobile, Alabama and 147 other locations · NCT06890884

• Ifinatamab deruxtecan alone or with other drugs for metastatic castration‑resistant prostate cancer

  This trial tests whether ifinatamab deruxtecan, given alone or with other cancer drugs, helps men with metastatic castration‑resistant prostate cancer by lowering PSA and controlling disease.

  Recruiting at 80 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 81 other locations · NCT06863272

• New treatment for relapsed high-grade serous ovarian cancer

  This study is testing a new drug combined with standard treatments to see if it can help people with relapsed high-grade serous ovarian cancer feel better and manage their disease.

  Recruiting at 40 sites Phase 1/2 Merck Sharp & Dohme LLC · New Haven, Connecticut and 40 other locations · NCT06843447

• Treatment for triple-negative breast cancer using sacituzumab tirumotecan and pembrolizumab

  This study is testing if a new treatment combining sacituzumab tirumotecan and pembrolizumab can help people with triple-negative breast cancer live longer and keep their cancer from getting worse compared to regular chemotherapy.

  Recruiting at 274 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 284 other locations · NCT06841354

• New treatment for high-risk non-muscle invasive bladder cancer

  This study is testing a new treatment combining Intismeran autogene with BCG to see if it can help people with high-risk non-muscle invasive bladder cancer who haven't responded to standard BCG therapy.

  Recruiting at 84 sites Phase 2 Merck Sharp & Dohme LLC · Bakersfield, California and 88 other locations · NCT06833073

• Evaluating a new treatment for recurrent ovarian cancer

  This study is testing a new treatment for women with recurrent ovarian cancer to see if it helps them live longer and feel better compared to standard care.

  Recruiting at 201 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 201 other locations · NCT06824467

• Evaluating MK-3120 for advanced solid tumors

  This study is testing a new treatment called MK-3120 to see if it can help people with advanced solid tumors that can't be removed by surgery.

  Recruiting at 28 sites Phase 1/2 Merck Sharp & Dohme LLC · Birmingham, Alabama and 48 other locations · NCT06818643

• New treatment approach for high-risk early-stage breast cancer

  This study is testing a new combination of treatments for people with high-risk early-stage triple-negative breast cancer to see if it can shrink tumors more than the usual treatment before surgery.

  Recruiting at 17 sites Phase 2 Merck Sharp & Dohme LLC · Santa Monica, California and 16 other locations · NCT06797635

• Evaluating new treatments for relapsed small cell lung cancer

  This study is testing two new drugs to see if they can help people with advanced small cell lung cancer that hasn't responded to other treatments.

  Recruiting at 44 sites Phase 1/2 Merck Sharp & Dohme LLC · Aurora, Colorado and 47 other locations · NCT06780137

• Combination therapies for esophageal squamous cell carcinoma (KEYMAKER-U06 Substudy 06E)

  This trial will test pembrolizumab together with an investigational antibody-drug conjugate (I-DXd), with or without chemotherapy, as a first-line treatment for people with locally advanced unresectable or metastatic esophageal squamous cell carcinoma.

  Recruiting at 52 sites Phase 1/2 Merck Sharp & Dohme LLC · Pittsburgh, Pennsylvania and 51 other locations · NCT06780111

• Investigational antibody–drug conjugates for previously treated stage IV squamous non-small cell lung cancer

  This trial tests whether antibody–drug conjugates can shrink or control metastatic squamous non-small cell lung cancer in people whose cancer progressed after immunotherapy and platinum chemotherapy.

  Recruiting at 46 sites Phase 2 Merck Sharp & Dohme LLC · Lexington, Kentucky and 45 other locations · NCT06780098

• Combining Pembrolizumab with Chemotherapy and Other Treatments for Advanced Lung Cancer

  This study is testing if combining the immunotherapy drug pembrolizumab with chemotherapy and other treatments can help people with untreated advanced lung cancer feel better and live longer.

  Recruiting at 37 sites Phase 2 Merck Sharp & Dohme LLC · Lexington, Kentucky and 40 other locations · NCT06731907

• Evaluating a new treatment combination for untreated diffuse large B-cell lymphoma

  This study is testing a new treatment that combines zilovertamab vedotin with standard chemotherapy to see if it helps people with untreated diffuse large B-cell lymphoma live longer without their cancer getting worse.

  Recruiting at 264 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 287 other locations · NCT06717347

• Treatment of advanced HER2 positive breast cancer with patritumab deruxtecan and other agents

  This study is testing a new treatment combining patritumab deruxtecan with other cancer drugs to see if it helps people with advanced HER2 positive breast cancer that can't be surgically removed.

  Recruiting at 18 sites Phase 1/2 Merck Sharp & Dohme LLC · Aurora, Colorado and 17 other locations · NCT06686394

• Using Molnupiravir to Prevent Severe COVID-19 in High-Risk Individuals

  This study is testing if the medication molnupiravir can help prevent severe COVID-19 in high-risk individuals who have recently shown symptoms of the virus.

  Recruiting at 200 sites Phase 3 Merck Sharp & Dohme LLC · Cullman, Alabama and 228 other locations · NCT06667700

• Suvorexant to treat insomnia in people with opioid use disorder.

  This trial tests whether suvorexant helps people with opioid use disorder fall asleep faster and stay asleep longer compared with placebo.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Garden Grove, California and 12 other locations · NCT06655883

• Evaluating a new vaccine for Epstein Barr virus in healthy adults

  This study is testing two new vaccines for the Epstein Barr virus in healthy adults to see if they are safe and effective at preventing related diseases.

  Recruiting at 6 sites Phase 1 Merck Sharp & Dohme LLC · Glendale, California and 8 other locations · NCT06655324

• Long-term safety and effectiveness of tulisokibart for Crohn's disease and ulcerative colitis

  This study is testing if the medication tulisokibart is safe and effective for people with moderate to severe Crohn's disease and ulcerative colitis over a longer period of time.

  Recruiting at 34 sites Phase 3 Merck Sharp & Dohme LLC · Bristol, Connecticut and 36 other locations · NCT06651281

• Combining pembrolizumab with intismeran autogene for non-small cell lung cancer treatment

  This study is testing if a new combination of a gene therapy and a cancer drug can help people with non-small cell lung cancer stay cancer-free after surgery.

  Recruiting at 234 sites Phase 3 Merck Sharp & Dohme LLC · Gilbert, Arizona and 245 other locations · NCT06623422

• Testing a new HPV vaccine in healthy adults

  This study is testing a new HPV vaccine in healthy adults to see if it is safe and works better than the current standard vaccine.

  Recruiting at 2 sites Phase 1 Merck Sharp & Dohme LLC · Anaheim, California and 3 other locations · NCT06623409

• Combination treatment for advanced esophageal cancer

  This study is testing a new combination of treatments for patients with advanced esophageal cancer to see if it is safe and effective for those who haven't had treatment before.

  Recruiting at 46 sites Phase 1/2 Merck Sharp & Dohme LLC · Tucson, Arizona and 49 other locations · NCT06469944

• Combination therapies for advanced gastroesophageal cancer

  This study is testing two different treatment combinations for people with advanced stomach cancer to see which one works better after their first treatment didn't help.

  Recruiting at 44 sites Phase 1/2 Merck Sharp & Dohme LLC · Tucson, Arizona and 45 other locations · NCT06445972

• Evaluating Tulisokibart for Moderate to Severe Crohn's Disease

  This study is testing if a new drug called tulisokibart can help people with moderate to severe Crohn's disease feel better compared to a placebo.

  Recruiting at 439 sites Phase 3 Merck Sharp & Dohme LLC · Dothan, Alabama and 498 other locations · NCT06430801

• Treatment for advanced gastrointestinal cancers using MK-2870 with or without chemotherapy

  This study is testing whether a new drug called MK-2870, alone or with chemotherapy, can help people with advanced gastrointestinal cancers like colorectal, pancreatic, or biliary tract cancer feel better and improve their treatment outcomes.

  Recruiting at 30 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 54 other locations · NCT06428409

• Combining pembrolizumab with or without sacituzumab tirumotecan for advanced lung cancer treatment

  This study is testing if adding a new drug called sacituzumab tirumotecan to the standard treatment with pembrolizumab can help people with advanced lung cancer live longer.

  Recruiting at 172 sites Phase 3 Merck Sharp & Dohme LLC · Little Rock, Arkansas and 216 other locations · NCT06422143

• Zilovertamab Vedotin for Pediatric and Young Adult Cancer Patients

  This study is testing a new drug called zilovertamab vedotin to see if it can help kids and young adults with certain types of cancer that haven't responded to other treatments.

  Recruiting at 70 sites Phase 1/2 Merck Sharp & Dohme LLC · Los Angeles, California and 70 other locations · NCT06395103

• Combination treatment for triple-negative breast cancer after surgery

  This study is testing a new combination treatment for people with triple-negative breast cancer who didn't fully respond to earlier therapy after surgery to see if it helps them stay cancer-free longer.

  Recruiting at 299 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 313 other locations · NCT06393374

• Evaluating the safety and effectiveness of bomedemstat for blood disorders

  This study is trying to see how safe and effective bomedemstat is for people with blood disorders like essential thrombocythemia and myelofibrosis who have been doing well on the treatment for at least six months.

  Recruiting at 18 sites Phase 3 Merck Sharp & Dohme LLC · Ann Arbor, Michigan and 20 other locations · NCT06351631

• Combining MK-1084 and Pembrolizumab for Advanced Lung Cancer with Specific Genetic Mutations

  This study is testing if a new combination of two drugs, MK-1084 and pembrolizumab, can help people with advanced lung cancer who have specific genetic mutations live longer and feel better.

  Recruiting at 188 sites Phase 3 Merck Sharp & Dohme LLC · Bakersfield, California and 246 other locations · NCT06345729

• Comparing sacituzumab tirumotecan and pembrolizumab to standard treatment for advanced breast cancer

  This study is testing if a new treatment combining sacituzumab tirumotecan and pembrolizumab can help people with advanced breast cancer live longer without their disease getting worse compared to standard treatments.

  Recruiting at 181 sites Phase 3 Merck Sharp & Dohme LLC · Chandler, Arizona and 258 other locations · NCT06312176

• Assessing the effectiveness of pembrolizumab with or without sacituzumab tirumotecan in lung cancer patients after surgery

  This study is testing if adding a new drug called sacituzumab tirumotecan to pembrolizumab can help lung cancer patients who had surgery live longer without their cancer coming back.

  Recruiting at 259 sites Phase 3 Merck Sharp & Dohme LLC · Little Rock, Arkansas and 270 other locations · NCT06312137

• Combining sacituzumab tirumotecan with pembrolizumab for advanced lung cancer

  This study is testing if combining two cancer treatments, sacituzumab tirumotecan and pembrolizumab, can help people with advanced lung cancer live longer compared to just using pembrolizumab alone.

  Recruiting at 154 sites Phase 3 Merck Sharp & Dohme LLC · Phoenix, Arizona and 219 other locations · NCT06170788

• Comparing Opevesostat to Other Hormonal Treatments for Advanced Prostate Cancer

  This study tests if a new treatment called opevesostat, combined with hormone therapy, can help men with advanced prostate cancer live longer and feel better compared to other hormonal treatments they might have already tried.

  Recruiting at 297 sites Phase 3 Merck Sharp & Dohme LLC · Tucson, Arizona and 329 other locations · NCT06136650

• Comparing Opevesostat to Other Treatments for Advanced Prostate Cancer

  This study is testing if a new drug called opevesostat can help people with advanced prostate cancer live longer and have fewer problems with their disease compared to other treatments they’ve already tried.

  Recruiting at 235 sites Phase 3 Merck Sharp & Dohme LLC · Orange, California and 287 other locations · NCT06136624

• Comparing Nemtabrutinib to Ibrutinib or Acalabrutinib for First Line Treatment of Chronic Lymphocytic Leukemia

  This study is testing if a new drug called nemtabrutinib works as well as or better than two existing treatments for people with chronic lymphocytic leukemia who haven’t had treatment before.

  Recruiting at 181 sites Phase 3 Merck Sharp & Dohme LLC · Mobile, Alabama and 205 other locations · NCT06136559

• Comparing two treatments for relapsed chronic lymphocytic leukemia

  This study is testing if a new combination of two drugs, nemtabrutinib and venetoclax, can help people with relapsed chronic lymphocytic leukemia live longer without their cancer getting worse compared to the usual treatment.

  Recruiting at 103 sites Phase 3 Merck Sharp & Dohme LLC · Springdale, Arkansas and 105 other locations · NCT05947851

• Evaluating vericiguat for heart failure in children

  This study is testing if a new heart medication called vericiguat can help children with heart failure feel better and improve their health compared to a placebo.

  Recruiting at 91 sites Phase 2/3 Merck Sharp & Dohme LLC · Los Angeles, California and 111 other locations · NCT05714085

• Evaluating Sotatercept in Children with Pulmonary Arterial Hypertension

  This study is testing a new drug called sotatercept in children with pulmonary arterial hypertension to see how well they tolerate it and how it affects their condition.

  Recruiting at 34 sites Phase 2 Merck Sharp & Dohme LLC · Los Angeles, California and 34 other locations · NCT05587712

• Evaluating new treatments for advanced esophageal cancer after prior PD-1 therapy

  This study is testing new treatment combinations for people with advanced esophageal cancer who didn't respond to previous PD-1 therapy to see if they can improve their outcomes.

  Recruiting at 48 sites Phase 1/2 Merck Sharp & Dohme LLC · Tucson, Arizona and 57 other locations · NCT05319730

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using zilovertamab vedotin

  This study is testing a new treatment called zilovertamab vedotin for adults with relapsed or refractory diffuse large B-cell lymphoma to see if it works better than standard care.

  Recruiting at 43 sites Phase 2/3 Merck Sharp & Dohme LLC · Glendale, Arizona and 134 other locations · NCT05139017

• Evaluating MK-1084 for advanced solid tumors with KRAS mutations

  This study is testing a new treatment called MK-1084, alone and with other drugs, to see if it helps people with advanced solid tumors that have a specific KRAS mutation.

  Recruiting at 67 sites Phase 1 Merck Sharp & Dohme LLC · Tampa, Florida and 74 other locations · NCT05067283

• Treatment of advanced tumors with belzutifan

  This study is testing a new medication called belzutifan to see if it can help people with advanced tumors related to specific conditions feel better and respond to treatment.

  Recruiting at 48 sites Phase 2 Merck Sharp & Dohme LLC · Los Angeles, California and 84 other locations · NCT04924075

• Evaluating the effects of nemtabrutinib in patients with blood cancers

  This study is testing a new oral medication called nemtabrutinib to see if it can help people with blood cancers like chronic lymphocytic leukemia and Waldenström's macroglobulinemia feel better and stay safe.

  Recruiting at 94 sites Phase 2 Merck Sharp & Dohme LLC · Springdale, Arkansas and 120 other locations · NCT04728893

• Using posaconazole to treat invasive fungal infections in young children

  This study tests how well a medication called posaconazole works for treating serious fungal infections in young children under 2 years old, using both an injection and a liquid form.

  Recruiting at 16 sites Phase 2 Merck Sharp & Dohme LLC · San Diego, California and 25 other locations · NCT04665037

• Doravirine treatment for HIV-infected children under 12 years old

  This study is testing a new HIV treatment called doravirine in children under 12 to see if it's safe and effective for them.

  Recruiting at 13 sites Phase 2 Merck Sharp & Dohme LLC · Aurora, Colorado and 25 other locations · NCT04375800

• Investigating Pembrolizumab Alone or With Chemotherapy for Non-Small Cell Lung Cancer

  This study is testing whether the drug pembrolizumab, alone or with chemotherapy, can help people with non-small cell lung cancer.

  Recruiting at 17 sites Merck Sharp & Dohme LLC · Gilbert, Arizona and 47 other locations · NCT04165798

• Efficacy and safety of pembrolizumab with or without chemotherapy for advanced lung cancer

  This study is testing if adding pembrolizumab to chemotherapy helps people with advanced lung cancer feel better and live longer compared to using pembrolizumab alone.

  Recruiting at 16 sites Phase 1/2 Merck Sharp & Dohme LLC · Gilbert, Arizona and 46 other locations · NCT04165070

• Long-term evaluation of pembrolizumab for patients with advanced tumors

  This study is testing how well pembrolizumab works and how safe it is for people with advanced tumors who have already been part of previous studies.

  Recruiting at 472 sites Phase 3 Merck Sharp & Dohme LLC · Tucson, Arizona and 781 other locations · NCT03486873

• Treatment of advanced solid tumors and lymphomas in children using pembrolizumab

  This study is testing if a new immunotherapy drug called pembrolizumab can help shrink or eliminate advanced solid tumors and lymphomas in children aged 12 to 18 who haven't responded to other treatments.

  Recruiting at 16 sites Phase 1/2 Merck Sharp & Dohme LLC · Aurora, Colorado and 15 other locations · NCT02332668

Quick answers

How many clinical trials run by Merck Sharp & Dohme LLC are recruiting right now?

115, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 69 countries. The most sites are in United States (93 trials), Spain (68 trials), South Korea (66 trials), Italy (62 trials), Israel (62 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 44, Phase 2: 25, Phase 1/2: 23, Phase 1: 14. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →